{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:22:33Z","timestamp":1785518553298,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41434-020-0121-4","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T15:03:09Z","timestamp":1578582189000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion"],"prefix":"10.1038","volume":"27","author":[{"given":"Leonardo","family":"Chicaybam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Viegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Vieira Code\u00e7o","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Ribeiro","family":"Batista-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Alves-Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bonecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Monte-M\u00f3r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-5822","authenticated-orcid":false,"given":"Mart\u00edn Hern\u00e1n","family":"Bonamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"121_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"121_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3109\/08830185.2011.595855","volume":"30","author":"L Chicaybam","year":"2011","unstructured":"Chicaybam L, Sodr\u00e9 AL, Bonamino M. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions. Int Rev Immunol. 2011;30:294\u2013311.","journal-title":"Int Rev Immunol"},{"key":"121_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"121_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"issue":"Dec","key":"121_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(Dec):2531\u201344.","journal-title":"N Engl J Med"},{"key":"121_CR6","doi-asserted-by":"publisher","first-page":"204062071984158","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.","journal-title":"Ther Adv Hematol"},{"key":"121_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"121_CR8","unstructured":"National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies. 2018. https:\/\/www.nice.org.uk\/guidance\/gid-ta10214\/documents\/appraisal-consultation-document. Accessed 07 May 2019."},{"key":"121_CR9","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.","journal-title":"Mol Ther Oncolytics"},{"key":"121_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/10409238.2017.1304354","volume":"52","author":"M Hudecek","year":"2017","unstructured":"Hudecek M, Izsv\u00e1k Z, Johnen S, Renner M, Thumann G, Ivics Z. Going non-viral: the sleeping beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol. 2017;52:355\u201380.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"121_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd.2018.74","volume":"17","author":"J Tang","year":"2018","unstructured":"Tang J, Hubbard-Lucey VM, Pearce L, O\u2019Donnell-Tormey J, Shalabi A. The global landscape of cancer cell therapy. Nat Rev Drug Discov. 2018;17:465\u20136.","journal-title":"Nat Rev Drug Discov"},{"issue":"399","key":"121_CR12","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"Donald M. O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Science Translational Medicine"},{"key":"121_CR13","doi-asserted-by":"publisher","unstructured":"Garfall AL, Stadtmauer EA, Hwang W-T, Lacey SF, Melenhorst JJ, Krevvata M, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018;3. https:\/\/doi.org\/10.1172\/jci.insight.120505.","DOI":"10.1172\/jci.insight.120505"},{"key":"121_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2018.05.009","volume":"369","author":"F Arabi","year":"2018","unstructured":"Arabi F, Torabi-Rahvar M, Shariati A, Ahmadbeigi N, Naderi M. Antigenic targets of CAR T cell therapy. A retrospective view on clinical trials. Exp Cell Res. 2018;369:1\u201310.","journal-title":"Exp Cell Res"},{"key":"121_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1047-x","volume":"14","author":"JE Vargas","year":"2016","unstructured":"Vargas JE, Chicaybam L, Stein RT, Tanuri A, Delgado-Ca\u00f1edo A, Bonamino MH. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med. 2016;14:288.","journal-title":"J Transl Med"},{"key":"121_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1089\/hum.2017.207","volume":"29","author":"CF Magnani","year":"2018","unstructured":"Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G, et al. Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with sleeping beauty transposon for the treatment of acute lymphoblastic leukemia. Hum Gene Ther. 2018;29:602\u201313.","journal-title":"Hum Gene Ther"},{"key":"121_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","volume":"31","author":"R Monjezi","year":"2017","unstructured":"Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors. Leukemia. 2017;31:186\u201394.","journal-title":"Leukemia"},{"key":"121_CR18","doi-asserted-by":"publisher","first-page":"e0128151","DOI":"10.1371\/journal.pone.0128151","volume":"10","author":"DC Deniger","year":"2015","unstructured":"Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, et al. Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS One. 2015;10:e0128151.","journal-title":"PLoS One"},{"key":"121_CR19","doi-asserted-by":"publisher","first-page":"e64138","DOI":"10.1371\/journal.pone.0064138","volume":"8","author":"H Singh","year":"2013","unstructured":"Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One. 2013;8:e64138.","journal-title":"PLoS One"},{"key":"121_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/hum.2018.218","volume":"30","author":"L Chicaybam","year":"2019","unstructured":"Chicaybam L, Abdo L, Carneiro M, Peixoto B, Viegas M, de Sousa P, et al. CAR T cells generated using sleeping beauty transposon vectors and expanded with an EBV-transformed lymphoblastoid cell line display antitumor activity in vitro and in vivo. Hum Gene Ther. 2019;30:511\u201322.","journal-title":"Hum Gene Ther"},{"key":"121_CR21","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126:3363\u201376.","journal-title":"J Clin Invest"},{"key":"121_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ijc.2910230206","volume":"23","author":"R Hurwitz","year":"1979","unstructured":"Hurwitz R, Hozier J, LeBien T, Minowada J, Gajl-Peczalska K, Kubonishi I, et al. Characterization of a leukemic cell line of the pre-B phenotype. Int J Cancer. 1979;23:174\u201380.","journal-title":"Int J Cancer"},{"key":"121_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood.V65.1.21.21","volume":"65","author":"RC Stong","year":"1985","unstructured":"Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985;65:21\u201331.","journal-title":"Blood"},{"key":"121_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.gt.3302141","volume":"11","author":"M Bonamino","year":"2004","unstructured":"Bonamino M, Serafini M, D\u2019Amico G, Gaipa G, Todisco E, Bernasconi S, et al. Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. Gene Ther. 2004;11:85\u201393.","journal-title":"Gene Ther"},{"key":"121_CR25","doi-asserted-by":"publisher","first-page":"e60298","DOI":"10.1371\/journal.pone.0060298","volume":"8","author":"L Chicaybam","year":"2013","unstructured":"Chicaybam L, Sodre AL, Curzio BA, Bonamino MH. An efficient low cost method for gene transfer to T lymphocytes. PLoS One. 2013;8:e60298.","journal-title":"PLoS One"},{"key":"121_CR26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CDLI.8.6.1131-1135.2001","volume":"8","author":"S Neri","year":"2001","unstructured":"Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol. 2001;8:1131\u20135.","journal-title":"Clin Diagn Lab Immunol"},{"key":"121_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2144\/000114018","volume":"54","author":"PS Walsh","year":"2013","unstructured":"Walsh PS, Metzger DA, Higushi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques. 2013;54:134\u20139.","journal-title":"Biotechniques"},{"key":"121_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/gt.2011.40","volume":"18","author":"Z Jin","year":"2011","unstructured":"Jin Z, Maiti S, Huls H, Singh H, Olivares S, M\u00e1t\u00e9s L, et al. The hyperactive sleeping beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. 2011;18:849\u201356.","journal-title":"Gene Ther"},{"key":"121_CR29","doi-asserted-by":"publisher","unstructured":"Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3. https:\/\/doi.org\/10.1172\/jci.insight.96976.","DOI":"10.1172\/jci.insight.96976"},{"key":"121_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390.","journal-title":"Immunity"},{"key":"121_CR31","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1073\/pnas.0503726102","volume":"102","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102:9571\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"121_CR32","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050\u20136.","journal-title":"Blood"},{"key":"121_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492\u2013500.","journal-title":"Leukemia"},{"key":"121_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fimmu.2013.00455","volume":"4","author":"A Legat","year":"2013","unstructured":"Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory receptor expression depends more dominantly on differentiation and activation than \u201cexhaustion\u201d of human CD8 T cells. Front Immunol. 2013;4:455.","journal-title":"Front Immunol"},{"key":"121_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fimmu.2015.00310","volume":"6","author":"SA Fuertes Marraco","year":"2015","unstructured":"Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310.","journal-title":"Front Immunol"},{"key":"121_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.","journal-title":"Nat Commun"},{"key":"121_CR37","first-page":"1137","volume":"117","author":"F Ceppi","year":"2018","unstructured":"Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, et al. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion. 2018;117:1137.","journal-title":"Transfusion"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0121-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0121-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0121-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:19Z","timestamp":1684617259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-0121-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["121"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-0121-4","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"9 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}